Osteoporosis in Menopause
On this page
Direct answer
Osteoporosis in menopause is bone loss caused by oestrogen withdrawal, and DEXA diagnoses it when the T-score is minus 2.5 or lower at the spine, hip or distal radius. FRAX estimates fracture risk, and treatment is considered for a T-score in the osteoporotic range, a fragility fracture or a FRAX probability above the local threshold. Calcium, vitamin D and weight-bearing exercise come first, with bisphosphonates as the usual first-line drugs and denosumab, raloxifene, hormone therapy and anabolic agents reserved for selected cases.
What you must remember
- Physiology: oestrogen withdrawal increases bone resorption, so bone loss is fastest in the early postmenopausal years.
- DEXA thresholds: normal is above minus 1.0, osteopenia lies between minus 1.0 and minus 2.5, and osteoporosis is minus 2.5 or lower, with severe disease when a fragility fracture coexists.
- FRAX: estimates the ten-year probability of major osteoporotic fracture and hip fracture from age, BMI, prior fracture, smoking and glucocorticoid use.
- Calcium and vitamin D: basic supplementation, with vitamin D deficiency common in Indian women and worth correcting before bisphosphonate therapy.
- Bisphosphonates: alendronate and risedronate orally, and zoledronic acid intravenously, with oesophageal irritation, osteonecrosis of the jaw and atypical femoral fracture as the key cautions.
- Denosumab: a RANKL inhibitor, with rebound vertebral fractures if it is stopped without a transition to another agent.
- Anabolic and selective agents: teriparatide or abaloparatide for severe osteoporosis, and raloxifene for vertebral fracture risk with a venous thromboembolism warning.
A graded decision for a 58-year-old with a T-score of minus 2.7
A 58-year-old woman, three years postmenopausal, has a DEXA scan showing a lumbar spine T-score of minus 2.7, with no prior fracture, no smoking and a family history of hip fracture.
- Check the T-score: A T-score of minus 2.7 meets the osteoporosis threshold, so treatment is indicated even without a fracture.
- Calculate FRAX: The family history of hip fracture adds to the score and produces a ten-year risk that supports treatment.
- Correct the foundations: Serum calcium and vitamin D are checked, and she is started on vitamin D and dietary calcium, with weight-bearing exercise and fall prevention advised.
- Choose the first drug: An oral bisphosphonate is the usual first option, taken fasting with water and remaining upright, with dental review before starting.
- Plan for denosumab: Denosumab is considered if oral therapy is not tolerated or is unsuitable, but the team plans the follow-on treatment in advance because stopping denosumab carries a rebound risk.
- Set hormone therapy aside: Hormone therapy could prevent bone loss, but its vasomotor and cardiovascular risks make it a secondary choice for her age.
The reasoning moves from the measurement to the risk, then to correction of the foundations, and only then to drug choice.
Where examiners test the threshold
Threshold and complication questions are the usual traps here.
- Trap: a T-score of minus 2.0 means osteoporosis Correct: minus 2.0 falls in the osteopenic range, and only minus 2.5 or lower defines osteoporosis; osteopenia alone is managed by FRAX and lifestyle measures rather than automatically by drugs.
- Trap: denosumab can simply be stopped Correct: it must be followed by a transition agent, because rebound vertebral fractures follow withdrawal without one.
- Trap: bisphosphonate harm is limited to oesophageal irritation Correct: osteonecrosis of the jaw and atypical femoral fracture are the two complications linked to long-term use and are commonly tested together.
Frequently asked questions
What T-score defines osteoporosis in menopausal women?
A T-score of minus 2.5 or lower on DEXA defines osteoporosis in menopausal women, measured at the spine, hip or distal radius. A T-score between minus 1.0 and minus 2.5 defines osteopenia, which is managed by fracture risk assessment rather than automatic drug treatment.
What does FRAX estimate in osteoporosis in menopause?
FRAX estimates the ten-year probability of major osteoporotic fracture and of hip fracture in osteoporosis in menopause. It combines age, BMI, prior fracture, smoking and glucocorticoid use, and treatment decisions use the thresholds applied locally.
Why is denosumab followed by another agent?
Denosumab is followed by another agent because stopping it without a transition causes rebound bone loss and multiple vertebral fractures. A bisphosphonate is commonly used as the follow-on treatment to maintain bone density after denosumab is withdrawn.
Which bisphosphonate complications are most often tested?
Osteonecrosis of the jaw and atypical femoral fracture are the two complications most often tested with long-term bisphosphonates in osteoporosis in menopause. Oesophageal irritation is the main early complication of oral agents and is avoided by taking them fasting, with water, while remaining upright.